MAIA Stock Price & Analysis — Maia Biotechnology Inc. (Healthcare >> Biotechnology)
MAIA FAQ
What is MAIA's ROE?
Maia Biotechnology Inc. reports a Return on Equity (ROE) of -87.34%.
What is MAIA's dividend yield?
Maia Biotechnology Inc. offers a dividend yield of 0.00%.
What is MAIA's Quality Score?
Our AI rates MAIA's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MAIA?
Our AI Timing Score for MAIA is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MAIA belong to?
Maia Biotechnology Inc. is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange
MAIA AI Analysis Summary
Our AI summary for MAIA: Maia Biotechnology Inc. (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at ROE of -87.34%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.36
Price
0.04
(3.03%)
Day Change
|
|
|---|
MAIA, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 43 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.36 |
| PBV / Sector |
2.98 / 44,022.72
|
| Earning Per Share | -0.40 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
0.81 M
GREAT
|
| Average 1W Daily Value |
0.53 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-05 08:00:30 |
| Symbol | MAIA |
| Name | MAIA BIOTECHNOLOGY INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 60.80 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 82.69 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 444 West Lake Street, Chicago, IL, United States, 60606
Phone: 312 416 8592
Website: https://maiabiotech.com
Sector: Healthcare >> Biotechnology
Description: MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap
Google